REVB earnings analysis
What we found in REVB's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Revelation Biosciences reported a net loss of $3.0 million for Q1 2026, compared to a net loss of $2.1 million for Q1 2025, indicating increased operational expenses. The Company's cash and cash equivalents stood at $14.1 million as of March 31, 2026, but they expressed substantial doubt about their ability to continue as a going concern without additional funding.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Increased Net Loss YoY
- Net loss increased to $3.0M in Q1 2026 from $2.1M in Q1 2025.
- Cash and Cash Equivalents
- Cash and cash equivalents totaled $14.1M as of March 31, 2026.
- R&D Expense Growth
- Research and development expenses rose from $858,830 in Q1 2025 to $1.4M in Q1 2026.
- GEM-AKI Manufacturing Costs
- GEM-AKI manufacturing expenses accounted for $314,304 of R&D costs in Q1 2026.
- Professional Fees Increase
- General and administrative expenses grew by $0.5M to $1.7M driven by professional fees and personnel costs.
- Funds Raised via Warrants
- Net proceeds of approximately $6.7M were raised from warrant exercises during Q1 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Doubt About Going Concern
- Management indicates that current cash may not support operations beyond one year.
- Recurring Operating Losses
- The Company has incurred significant losses since inception, with a total accumulated deficit of $52.4M.
- Potential Nasdaq Delisting
- Risk of delisting if the Company fails to meet Nasdaq's capitalization and liquidity requirements.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-3.09
What they said about what is next.
Outlook deferred to earnings press release / call.
The filing reads worse than the one before it.
What came before.
- 10-K · February 26, 2026
- Revelation Biosciences is a clinical-stage company developing Gemini (PHAD®) as an immunomodulatory therapy focused on AKI and CKD. The 10-K reports an end‑of‑2025 regulatory milestone — the company “obtained agreement…
- 10-Q · November 6, 2025
- Revelation Biosciences reported a three-month net loss of $1,907,176 for the period ended September 30, 2025 (improving $334,389 vs. $2,241,565 in the prior-year quarter) and a nine‑month net loss of $6,402,643…
- 10-Q · May 8, 2025
- Revelation Biosciences reported a Q1 net loss of $2,051,085 (Q1 2024: $2,681,433), improving by $630,348 year-over-year, and reported EPS of -$2.11. R&D and G&A rose modestly to $858,830 and $1,236,157, respectively.…
- 10-Q · November 8, 2024
- Revelation Biosciences reported a Q3 2024 net loss of $2,241,565 (EPS -$0.84), an improvement versus Q3 2023 net loss of $2,628,376 (EPS -$9.94). Operating expenses declined to $1,796,686 from $2,777,897, driven by…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing REVB makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever